S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Agilent Technologies, Inc.

A · Healthcare · · USD
150.86 USD
+0.00 (0.59%)
● Updated 2026-09-07 20:34 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Long-term (Investment)

74
/ 100
Technical 75
Trend & RS 74
Momentum 80
Fundamental 89
Macro 64
Liquidity 48
ComponentScoreWeight
Technical 75.0 10%
Trend & RS 74.1 10%
Momentum 80.3 5%
Fundamental 88.9 40%
Macro 64.4 15%
Liquidity 48.0 20%

Trade Setup

Entry 150.86
Stop Loss 141.84 (6.0%)
Target 1 (1:1) 159.88 (+6.0%)
Target 2 (2:1) 168.90 (+12.0%)
ATR(14) 4.51 (3.0%)
Risk per Share 9.02
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 39.8 -0.41
Momentum 80.3 +1.21
Quality 55.1 +0.20
Composite 58.4

Quality Scores

Piotroski F-Score 7 /9 — Strong
✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 7.56 — Safe Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 29.8 22.0 +35% above
P/B Ratio 5.8 4.0 Above
Dividend Yield 68.0% 1.5% Above avg

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
81.15
vs
Market Price
150.86
Upside
-46.2%
Margin of Safety -85.9%
Stage 1 PV (5yr FCF)5,578,171,321
Terminal Value PV17,302,182,581
Total Enterprise Value22,880,353,902

Assumptions

Base FCF1,143,653,338
Growth Rate (5yr)8.1%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
47.93%
Full Kelly
23.97%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 74/100. Estimated win rate 62%, avg win 9.4%, avg loss 3.5%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
54.03
RSI(14)
2.7659
MACD

Relative Strength (RS) WEAK RS

35
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↑ RISING (+6.9% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (10d since high)
Sector Outperformance +3.8% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
WEAK RS: Underperformer — the stock is lagging the market. Avoid until RS trend reverses upward.

Technical Indicators

IndicatorValueSignal
Rsi 54.03 NEUTRAL
Macd 2.7659 BEARISH
Ma Cross 142.32 / 131.23 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.79x NORMAL

Key Levels

LevelPrice
52-Week High163.75
Bollinger Upper158.96
SMA(200)131.23
SMA(50)142.32
SMA(20)152.12
Current Price150.86
Bollinger Lower145.28
52-Week Low108.35
ATR(14)4.51

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.2x Normal bar — no special VSA pattern
2026-09-01 Normal 1.18x Normal bar — no special VSA pattern
2026-09-02 Normal 1.36x Normal bar — no special VSA pattern
2026-09-03 Normal 0.98x Normal bar — no special VSA pattern
2026-09-04 Normal 0.79x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 155.68 Above Kijun
Kijun-sen (26) 149.76 Base line
Senkou A 152.72 Leading span A
Senkou B 144.38 Leading span B
Cloud 144.38 – 152.72 Bullish (Green)
Price vs Cloud 150.86 Inside Cloud
Chikou Span 138.37 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BEARISH
BB: 145.28 – 158.96  |  KC: 145.54 – 158.7

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bullish RSI 10

Anchored VWAP

VWAP: 137.34 Anchor: 2026-05-20 (52w Low) ABOVE AVWAP +9.8%

Heikin-Ashi Trend

BEARISH Full data via /api/advanced/A

Valuation

MetricValue
Market Cap42.54B
P/E (TTM)29.76
Forward P/EN/A
P/B5.78
EPS5.07

Financial Health

MetricValue
Revenue Growth8.1%
Profit Margin19.5%
ROE21.0%
Debt/Equity56.34
Current Ratio2.05
Dividend Yield68.0%
Payout RatioN/A
Beta1.24

Trading Data

150.86
Open
150.86
Day High
150.86
Day Low
1.81M
Volume (0.8x avg)

Recent News (8)

Agilent (A) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · 2026-09-07
Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?
Zacks · 2026-09-07
Amgen Stock Signals Its Confidence. The Market Agrees.
Trefis · 2026-09-02
Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
InvestorsHub · 2026-09-01
Agilent (A) Q3 2026 Earnings Call Transcript
Motley Fool · 2026-08-31
International Markets and Agilent (A): A Deep Dive for Investors
Zacks · 2026-08-31
Agilent (NYSE) Expanded Non-GAAP Margin 320 bps. How Much Is Repeatable?
Insider Monkey · 2026-08-29
A Q2 Deep Dive: Product Momentum, China Recovery, and Operating Leverage Drive Results
StockStory · 2026-08-28

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —